WrxFlo Secures $3.4

Everhaze

Everhaze is building the intelligent operating layer for the future of PR and communications. Built for teams under pressure to move faster, deliver sharper insight and prove greater value, Everhaze brings together media intelligence, monitoring, narrative analysis, outreach and reporting in one connected workflow. Our mission is to help communications professionals meet the pace of change without sacrificing the people, judgement and creativity that make great work possible.

CJK

CJK is one of the leading M&E contractors in Ireland, delivering mission critical mechanical and electrical solutions across high demand sectors. Our expertise spans Data Centres, Commercial, Energy, Aviation, Pharmaceuticals and Life Sciences, where we operate in complex, fast paced environments. We focus on safety, programme certainty, and quality, ensuring reliable delivery on every project.

Zenith Ai

Zenith is building a software BioStudio that mobilises best-in-class machine learning for future Biotechnology. Our vision is to be the standard for end-to-end AI creation that delivers in the real world. Founded in 2020 by a team of experienced and successful AI entrepreneurs, our team has rapidly progressed the development of our core software which enables non-experts to rapidly build and deploy purpose-built AI applications. At Zenith the customer use-case comes first and to achieve this, AI requires tooling that is wholly intuitive and light-years ahead of those in use today. We partner with leaders in biology, life sciences and robotics.

NíoSync Limited

At ?í?????, we’re focused on ensuring that innovation reaches European patients. For smaller companies with a single asset, Europe is often an unassailable maze of country specific requirements and slow reimbursement processes which makes launching a single product prohibitively costly and complex. At ?í?????, we are building a platform with the scale, leverage, and intelligence to cut through this complexity, bringing life-saving medicines to patients in Europe. Because innovation that patients can’t access is innovation wasted.

Nazata Bio

High blood pressure affects 1.3 billion people, is the #1 risk factor for death worldwide and the main cause of heart attacks, strokes, and heart failure. Nazata Bio is a digital therapeutics startup - it empowers patients to reduce their blood pressure via an app that acts as a specialist dietitian, an exercise coach and a behavioural scientist. Each patient's treatment is tailored based on a machine learning personalisation algorithm, so that every patient receives treatment optimised for their unique needs. Ultimately, this leads to the optimal reduction in blood pressure. For further details at https://www.nazatabio.com